Physician profile
Soidjon D Khodjaev
NPI 1629313572
$14,388.68
in general payments reported to CMS, 2019-2025
30 companies · $6,402 in 2025
The $6,402 reported for 2025 was more than what 93% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $872 · 2021: $1,026 · 2022: $1,567 · 2023: $1,386 · 2024: $2,918 · 2025: $6,402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,546 · Consulting Fee: $3,275 · Travel and Lodging: $2,724 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,545.71 |
| Consulting Fee | $3,275.00 |
| Travel and Lodging | $2,724.24 |
| Education | $160.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $5,483.11 | 2020-2025 | Uptravi, Opsumit |
| Cvrx, INC. | $2,419.27 | 2023-2025 | Barostim Neo System |
| Abiomed | $1,921.63 | 2022-2025 | Impella |
| Abbott Laboratories | $633.13 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Heartmate Touch |
| Novartis Pharmaceuticals Corporation | $583.87 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $548.71 | 2020-2025 | Wainua, Farxiga |
| Merck Sharp & Dohme LLC | $371.46 | 2022-2025 | Winrevair, Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $265.05 | 2022-2025 | Camzyos |
| Janssen Pharmaceuticals, INC | $231.28 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.00 | 2020-2024 | Jardiance |
| Inari Medical, INC. | $153.41 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $144.31 | 2019-2025 | Lifevest |
| Livanova USA, INC. | $142.83 | 2022 | |
| Pfizer INC. | $137.16 | 2021-2024 | |
| Impulse Dynamics (USA) INC. | $123.17 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akcea Therapeutics, INC. | $120.22 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $109.76 | 2023-2024 | Inpefa |
| Alnylam Pharmaceuticals INC. | $107.16 | 2021-2025 | Onpattro, Amvuttra |
| Edwards Lifesciences Corporation | $99.22 | 2020-2023 | Sapien 3 Ultra Resilia |
| Novo Nordisk INC | $96.01 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Scpharmaceuticals INC. | $82.86 | 2024-2025 | |
| Amgen INC. | $79.07 | 2023-2024 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $66.82 | 2022-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $60.03 | 2023 | Arcalyst |
| Liquidia Technologies, INC. | $59.50 | 2025 | Yutrepia |
| United Therapeutics Corporation | $41.97 | 2019-2024 | Tyvaso |
| Kestra Medical Technology Services, INC. | $39.75 | 2022-2023 | Assure Wcd |
| Atricure, INC. | $30.40 | 2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Chiesi USA, INC. | $22.52 | 2022 | |
| Glaxosmithkline, LLC. | $21.00 | 2023 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Soidjon Khodjaev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.